Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2025 20:22 ET | Source: InnoCare Pharma

Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL.
December 08, 2025 21:04 ET | Source: InnoCare Pharma

Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

The study of mesutoclax in the treatment of r/r MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster.
December 08, 2025 19:45 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven...
December 08, 2025 19:45 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus...
December 08, 2025 19:45 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60%...
December 07, 2025 20:10 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly...
December 07, 2025 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal...
December 06, 2025 10:15 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility...
December 05, 2025 22:11 ET | Source: Junshi Biosciences

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Promising long-term survival results from toripalimab's JUPITER-02 and JUPITER-06 presented at the ESMO ASIA
December 05, 2025 10:19 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

BLA of Roconkibart (IL-17A) for the treatment of moderate to severe plaque psoriasis has been accepted by the NMPA